当前位置: 首页 >> 检索结果
127. Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
作者: Patricia A Ganz.;Reena S Cecchini.;Thomas B Julian.;Richard G Margolese.;Joseph P Costantino.;Laura A Vallow.;Kathy S Albain.;Patrick W Whitworth.;Mary E Cianfrocca.;Adam M Brufsky.;Howard M Gross.;Gamini S Soori.;Judith O Hopkins.;Louis Fehrenbacher.;Keren Sturtz.;Timothy F Wozniak.;Thomas E Seay.;Eleftherios P Mamounas.;Norman Wolmark.
来源: Lancet. 2016年387卷10021期857-65页
The NSABP B-35 trial compared 5 years of treatment with anastrozole versus tamoxifen for reducing subsequent occurrence of breast cancer in postmenopausal patients with ductal carcinoma in situ. This report assesses the effect of these drugs on quality of life and symptoms.
130. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
作者: Richard G Margolese.;Reena S Cecchini.;Thomas B Julian.;Patricia A Ganz.;Joseph P Costantino.;Laura A Vallow.;Kathy S Albain.;Patrick W Whitworth.;Mary E Cianfrocca.;Adam M Brufsky.;Howard M Gross.;Gamini S Soori.;Judith O Hopkins.;Louis Fehrenbacher.;Keren Sturtz.;Timothy F Wozniak.;Thomas E Seay.;Eleftherios P Mamounas.;Norman Wolmark.
来源: Lancet. 2016年387卷10021期849-56页
Ductal carcinoma in situ is currently managed with excision, radiotherapy, and adjuvant hormone therapy, usually tamoxifen. We postulated that an aromatase inhibitor would be safer and more effective. We therefore undertook this trial to compare anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy.
131. Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial.
作者: John F Forbes.;Ivana Sestak.;Anthony Howell.;Bernardo Bonanni.;Nigel Bundred.;Christelle Levy.;Gunter von Minckwitz.;Wolfgang Eiermann.;Patrick Neven.;Michael Stierer.;Chris Holcombe.;Robert E Coleman.;Louise Jones.;Ian Ellis.;Jack Cuzick.; .
来源: Lancet. 2016年387卷10021期866-73页
Third-generation aromatase inhibitors are more effective than tamoxifen for preventing recurrence in postmenopausal women with hormone-receptor-positive invasive breast cancer. However, it is not known whether anastrozole is more effective than tamoxifen for women with hormone-receptor-positive ductal carcinoma in situ (DCIS). Here, we compare the efficacy of anastrozole with that of tamoxifen in postmenopausal women with hormone-receptor-positive DCIS.
134. Does happiness itself directly affect mortality? The prospective UK Million Women Study.
作者: Bette Liu.;Sarah Floud.;Kirstin Pirie.;Jane Green.;Richard Peto.;Valerie Beral.; .
来源: Lancet. 2016年387卷10021期874-81页
Poor health can cause unhappiness and poor health increases mortality. Previous reports of reduced mortality associated with happiness could be due to the increased mortality of people who are unhappy because of their poor health. Also, unhappiness might be associated with lifestyle factors that can affect mortality. We aimed to establish whether, after allowing for the poor health and lifestyle of people who are unhappy, any robust evidence remains that happiness or related subjective measures of wellbeing directly reduce mortality.
136. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial.
作者: Johan A Maertens.;Issam I Raad.;Kieren A Marr.;Thomas F Patterson.;Dimitrios P Kontoyiannis.;Oliver A Cornely.;Eric J Bow.;Galia Rahav.;Dionysios Neofytos.;Mickael Aoun.;John W Baddley.;Michael Giladi.;Werner J Heinz.;Raoul Herbrecht.;William Hope.;Meinolf Karthaus.;Dong-Gun Lee.;Olivier Lortholary.;Vicki A Morrison.;Ilana Oren.;Dominik Selleslag.;Shmuel Shoham.;George R Thompson.;Misun Lee.;Rochelle M Maher.;Anne-Hortense Schmitt-Hoffmann.;Bernhardt Zeiher.;Andrew J Ullmann.
来源: Lancet. 2016年387卷10020期760-9页
Isavuconazole is a novel triazole with broad-spectrum antifungal activity. The SECURE trial assessed efficacy and safety of isavuconazole versus voriconazole in patients with invasive mould disease.
138. Glomerulonephritis triggered by a chronically infected left ventricular assist device.
作者: Turgay Saritas.;Vincent Brandenburg.;Giuseppina Federico.;Hermann-Josef Gröne.;Jürgen Floege.;Marcus-Johannes Moeller.;Ajay Moza.
来源: Lancet. 2015年386卷10010期2363-4页 |